Catalyst Biosciences Inc (NASDAQ:CBIO)’s stock price rose 7.2% during mid-day trading on Thursday . The stock traded as high as $4.66 and last traded at $4.61. Approximately 187,087 shares traded hands during trading, a decline of 32% from the average daily volume of 275,445 shares. The stock had previously closed at $4.30.
Several research firms have weighed in on CBIO. Zacks Investment Research cut Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, August 24th. Ci Capital restated a “buy” rating and issued a $18.00 target price on shares of Catalyst Biosciences in a research note on Thursday, August 6th. Finally, Raymond James set a $20.00 target price on Catalyst Biosciences and gave the company an “outperform” rating in a research note on Friday, August 7th.
The stock has a market capitalization of $101.71 million, a P/E ratio of -1.32 and a beta of 2.19. The company has a 50 day simple moving average of $4.89 and a 200-day simple moving average of $5.57.
Several large investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP raised its stake in shares of Catalyst Biosciences by 49.6% during the 2nd quarter. Engineers Gate Manager LP now owns 19,300 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 6,400 shares during the period. Public Employees Retirement System of Ohio bought a new position in Catalyst Biosciences in the 2nd quarter worth about $55,000. BlackRock Inc. increased its stake in Catalyst Biosciences by 3.5% in the 1st quarter. BlackRock Inc. now owns 280,751 shares of the biopharmaceutical company’s stock worth $1,227,000 after acquiring an additional 9,563 shares during the last quarter. American International Group Inc. bought a new position in Catalyst Biosciences in the 2nd quarter worth about $63,000. Finally, Geode Capital Management LLC increased its stake in Catalyst Biosciences by 11.3% in the 1st quarter. Geode Capital Management LLC now owns 118,668 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 12,076 shares during the last quarter. Institutional investors own 63.16% of the company’s stock.
About Catalyst Biosciences (NASDAQ:CBIO)
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Recommended Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.